Literature DB >> 902672

Hypotensive effects of sodium volume depletion and 1-sar-8-ala-angiotensin II in relation to plasma renin in hypertensive patients.

R Fagard, A Amery, P Lijnen, T Reybrouck.   

Abstract

The hypotensive effect of acute sodium volume depletion, produced by chlorthalidone and a low sodium diet, was inversely related to the plasma renin concentration (PRC) in 13 hypertensive patients of varying aetiology (r = 0.61; p less than 0.05); weight reduction induced by this therapy was not related to PRC (r = 0.12; p greater than 0.1). The angiotensin II antagonist 1-sar-8-ala-angiotensin II failed to reduce arterial pressure when the patients ingested 130 mEq sodium per day, but pressure fell when it was infused during sodium volume depletion, except when PRC remained low; the changes in pressure were related to the plasma renin level (r = 0.78; p less than o.005). The combined hypotensive response to acute sodium volume depletion and to angiotensin II blockade during sodium volume depletion was not related to PRC (r = 0.15; p greater than 0.1). The results demonstrate that acute sodium volume depletion caused similar weight loss in patients with high and low PRC values, and it would have had similar hypotensive effects but for angiotensin-induced vasoconstriction in the high renin patients. Since 1-sar-8-ala-angiotensin II also reduced arterial pressure in 6 patients during chronic diuretic therapy, angiotensin II must still induce vasoconstriction in these circumstances.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 902672     DOI: 10.1007/bf00561398

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Haemodynamic effects of Sar1-Ala8-angiotensin II in patients with renovascular hypertension.

Authors:  R Fagard; A Amery; P Ljnen; T Reybrouck; L Billiet
Journal:  Prog Biochem Pharmacol       Date:  1976

2.  Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles.

Authors:  J H Laragh
Journal:  Am J Med       Date:  1973-09       Impact factor: 4.965

3.  Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone.

Authors:  E D Vaughan; J H Laragh; I Gavras; F R Bühler; H Gavras; H R Brunner; L Baer
Journal:  Am J Cardiol       Date:  1973-09-20       Impact factor: 2.778

4.  Spironolactone and hydrochlorothiazide in essential hypertension. Blood pressure response and plasma renin activity.

Authors:  E V Adlin; A D Marks; B J Channick
Journal:  Arch Intern Med       Date:  1972-12

5.  Hypertension and low plasma renin activity: presumptive evidence for mineralocorticoid excess.

Authors:  R F Spark; J C Melby
Journal:  Ann Intern Med       Date:  1971-12       Impact factor: 25.391

6.  Effect of spironolactone in hypertensive patients.

Authors:  M G Crane; J J Harris
Journal:  Am J Med Sci       Date:  1970-12       Impact factor: 2.378

7.  Plasma renin concentration and the hypotensive effect of bendrofluazide and of atenolol.

Authors:  R Fagard; A Amery; J F Deplaen; P Lijnen; A Missotten
Journal:  Clin Sci Mol Med Suppl       Date:  1976-12

8.  Editorial: When to measure renin.

Authors: 
Journal:  Lancet       Date:  1975-04-05       Impact factor: 79.321

9.  Improved assay methods for renin "concentration" and "activity" in human plasma. Methods using selective denaturation of renin substrate.

Authors:  S L Skinner
Journal:  Circ Res       Date:  1967-04       Impact factor: 17.367

10.  Renin profiling in hypertension and its use in treatment with propranolol and chlorthalidone.

Authors:  J W Woods; A W Pittman; C C Pulliam; E E Werk; W Waider; C A Allen
Journal:  N Engl J Med       Date:  1976-05-20       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.